10 Most Read Articles—November 2008

[Barbara2]

Address didn't work...I'll keep trying.

The Oncology Report—Fall 2008
44th Annual Meeting of the American Society of Clinical Oncology
Comprehensive reports from the 44th annual meeting of the American Society of Clinical Oncology.

McCain vs Obama: How Will Their Health Care Plans Change Cancer Care?
2008 Oct 16, Lee Schwartzberg, MD, FACP, Editor-in-Chief
The election outcome will clearly have a profound impact on the lives of cancer patients and their providers.

Vitamins, Micronutrients, and Cancer Prevention: Where Do We Stand?
2008 Nov 18, Lee Schwartzberg, MD, Editor-in-Chief
The negative results of SELECT and other recent trials of antioxidants offer important lessons for future research.

Alternative Revenue Sources a Boon to Community Oncologists
Elsevier Global Medical News, 2008 Nov 9, R Finn
Declines in reimbursement coupled with increases in overhead create a dilemma for community oncologists.

Men With BRCA Mutations: Risk Management Strategies Breast, 2008 Oct 1, HB Mohamad, et al Based on currently available evidence, this review offers guidelines for monitoring male BRCA carriers for the development of various cancers. Endocrine Therapy Adverse Effects Predict Breast Cancer RecurrenceLancet Oncol, 2008 Oct 30, J Cuzick, et al Early appearance of vasomotor and joint symptoms from endocrine therapy for breast cancer was linked with a lower rate of recurrence. Bevacizumab in Lung Cancer Trial Is Negative for Overall Survival Elsevier Global Medical News, 2008 Oct 9, P Wendling Bevacizumab combined with cisplatin and gemcitabine chemo did not improve overall survival in the first-line treatment of NSCLC. Oral Tyrosine Kinase Inhibitors May Cause Hypothyroidism Elsevier Global Medical News, 2008 Nov 9, B Jancin Hypothyroidism is a frequent complication of many of the oral tyrosine kinase inhibitors being developed to treat malignancies. Circulating Tumor Cell Dx Is Technology to Watch in 2009 The Gray Sheet, 2008 Nov 17, D Filmore Use of circulating tumor cell assays to predict chemotherapy success will be the most significant medical innovation to break through in 2009. Gardasil Effective in Preventing HPV-Related Disease in Males Merck Press Release, 2008 Nov 13 Gardasil prevented 90% of external genital lesions caused by HPV types 6, 11, 16, and 18 in a pivotal phase III study in males aged 16 to 26 years.